26
|
Zelenetz A, Zinzani P, Buske C, Ribrag V, Cunningham D, Jurczak W, Abrisqueta P, Agajanian R, Chaudhry A, Kayyal T, Wood J, Llorin-Sangalang J, Brown J. A PIVOTAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO-ARM, PHASE 2 STUDY OF ME-401 INVESTIGATING TWO DOSING SCHEDULES IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AFTER FAILURE OF TWO OR MORE PRIOR SYSTEMIC THERAPIES. Hematol Oncol 2019. [DOI: 10.1002/hon.2_2632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
27
|
Le Gouill S, Beldi-Ferchiou A, Cacheux V, Salles G, Canioni D, Bodet-Milin C, Alcantara M, Delwail V, Gastinne T, Thieblemont C, Maisonneuve H, Lamy de la Chapelle T, Oberic L, Bouabdallah K, Ribrag V, Delfau-Larue M, Macintyre E, Hermine O. OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS. RESULTS OF LYMA-101 TRIAL, A LYSA GROUP STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.14_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
28
|
Michot J, Camara-Clayette V, Detolle A, Chahine C, Lazarovici J, Danu A, Bosq J, Ghez D, Romano-Martin P, Dartigues P, Arfi-Rouche J, Bahleda R, Rahali W, Varga A, Baldini C, Tselikas L, Paume C, Lecourt H, Cotteret S, Vergé V, Soria J, Massard C, Ribrag V. FEASIBILITY AND BENEFIT OF MOLECULARLY-INFORMED ENROLLMENT INTO EARLY PHASE CLINICAL TRIALS FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.142_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
29
|
Mollaret E, Gomez E, Nadel B, Naiglin L, Anquetin M, Barau C, Baseggio L, Bret C, Brisou G, Brousset P, Camara-Clayette V, Cartron G, Da Cunha K, Dartigues P, Dupuis J, Ghaleh B, Gravelle P, Houot R, Karmous-Gadacha O, Laurent C, Moreaux J, Pangault C, Ribrag V, Salles G, Szablewski V, Thouault V, Uze G, Verge V, Ysebaert L, Gaulard P, Fest T. CeVi: A UNIQUE CRYOPRESERVED HUMAN VIABLE CELL COLLECTION FROM LYMPHOMA PATIENTS, A CALYM INITIATIVE TO ACCELERATE INNOVATION AND ITS TRANSFER TO LYMPHOMA FIELD. Hematol Oncol 2019. [DOI: 10.1002/hon.38_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
30
|
Zinzani P, Armand P, Ribrag V, Michot J, Kuruvilla J, Zhu Y, Farooqui M, Nahar A, Moskowitz C. PHASE 1B KEYNOTE-013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF >4 YEARS OF FOLLOW-UP. Hematol Oncol 2019. [DOI: 10.1002/hon.106_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
31
|
Delfau-Larue M, Boulland M, Feugier P, Maisonneuve H, Casasnovas O, Haioun C, Pica G, Lamy de la Chapelle T, Ysebaert L, Tilly H, Eisenmann J, Le Gouil S, Ribrag V, Jardel H, Glaisner S, Cartron G, Salles G, Xerri L, Fest T, Morschhauser F. RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.77_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
32
|
Leroy L, Satar T, Baldini C, Martin-Romano P, Hollebecque A, Michot JM, Ribrag V, Massard C, Paoletti X, Postel Vinay S. Safety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes? Ann Oncol 2019. [DOI: 10.1093/annonc/mdz029.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Vuagnat P, Baldini C, Verlingue L, Martin Romano P, Varga A, Hollebecque A, Postel-Vinay S, Gazzah A, Bahleda R, Marabelle A, Ribrag V, Champiat S, Michot JM, Soria JC, Massard C. Molecular alterations and matched treatment in older patients: Results from the MOSCATO 01 trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy303.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Bernard-Tessier A, Baldini C, Castanon Alvarez E, Ammari S, Martin Romano P, Champiat S, Hollebecque A, Postel-Vinay S, Varga A, Bahleda R, Gazzah A, Michot JM, Ribrag V, Armand JP, Marabelle A, Soria JC, Massard C. Patterns of progression to immune checkpoint targeted monoclonal antibodies in phase I trials. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Baldini C, Martin-Romano P, Voisin AL, Danlos F, Champiat S, Laghouati S, Kfouri M, Vincent H, Nagera C, Postel-Vinay S, Varga A, Ribrag V, Besse B, Hollebecque A, Lambotte O, Michot JM, Soria JC, Massard C, Marabelle A. Incidence of immune related adverse events in patients 70 years old treated with anti-PD-(L)1 therapy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.079] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Abdelshafy M, El Dakdouki Y, Verlingue L, Hollebecque A, Lacroix L, Postel-Vinay S, Varga A, Balheda R, Michot JM, Marabelle A, Rouleau E, Solary E, de Baere T, Angevin E, Ribrag V, Michiels S, André F, Scoazec JY, Soria JC, Massard C. Precision medicine for patients with rare cancers: An effective strategy within the prospective MOSCATO trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy303.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Vozy A, Simonaggio A, Auclin E, Mezquita L, Baldini C, Martin-Romano P, Pistilli B, Gazzah A, Bahleda R, Ribrag V, Postel-Vinay S, Champiat S, Soria JC, André F, Massard C, Besse B, Delaloge S, Varga A. Applicability of the lung immune prognostic index (LIPI) to metastatic triple negative breast cancer (mTNBC) patients treated with immune checkpoint targeted monoclonal antibodies (ICT mAbs). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.286] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Boros A, Ribrag V, Deutsch É, Chargari C, Izar F. [Radiation therapy planning for Hodgkin lymphoma: Focus on intensity-modulated radiotherapy, gating, protons. Which techniques to best deliver radiation?]. Cancer Radiother 2018; 22:404-410. [PMID: 30076071 DOI: 10.1016/j.canrad.2018.07.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2018] [Accepted: 06/21/2018] [Indexed: 11/28/2022]
Abstract
The optimization of radiotherapy in these young and long-lived survivors raises the question about the interest of using modern techniques to allow a better distribution of the dose. The choice of the irradiation technique must take into account the incidence of side effects related to radiation. In this context, the definition of the target volumes as well as the verification and monitoring of the delivered processing are essential. International recommendations for treatment fields are based on the "involved node radiotherapy" concept. The best irradiation technique to use remains to be defined. The use of intensity-modulated radiotherapy improves the coverage and reduces the dose to the organs at risk with a variable gain depending on the topography of the lymph nodes: upper or lower mediastinum, right or left lateralization, the techniques used. The deep inspiration breath-hold technique allows an increase of the pulmonary volume, extension of the mediastinum with an up down of the heart which make possible to move the planning target volume away from the cardiac structures. The volumetric-modulated arctherapy technique with several arches can be particularly interesting to reduce the dose to the breasts, as well as tomotherapy when bulky disease. Proton therapy with the Bragg peak specificity can play a key role in limiting doses to organs at risk, when robust planning that will take into account geometric and physical uncertainties is available. The heterogeneity of Hodgkin lymphomas in terms of volume, shape and initial location are the key elements to take into account when choosing the preferred radiotherapy technique.
Collapse
|
39
|
Sall FB, Germini D, Kovina AP, Ribrag V, Wiels J, Toure AO, Iarovaia OV, Lipinski M, Vassetzky Y. Effect of Environmental Factors on Nuclear Organization and Transformation of Human B Lymphocytes. BIOCHEMISTRY (MOSCOW) 2018; 83:402-410. [DOI: 10.1134/s0006297918040119] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
40
|
Saleh K, Michot J, Schernberg A, Danu A, Lazarovici J, Ghez D, Girinsky T, Khalife-Saleh N, Mazeron R, Ribrag V, Boros A. EP-1249: Repeated low-dose radiation therapy in indolent Non-Hodgkin Lymphoma patients. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31559-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
41
|
Michot JM, Bouabdallah R, Doorduijn J, Vitolo U, Kersten M, Chiappella A, Zinzani P, Pourdehnad M, Nikolova Z, Ribrag V. CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy048.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Herin H, Castanon E, Dyevre V, Aspeslagh S, Marabelle A, Postel-Vinay S, Varga A, Gazzah A, Ribrag V, Bahleda R, Michot JM, Mir O, Massard C, Hollebecque A, Soria JC, Baldini C. Immunotherapy phase I trials in patients over 70 years with advanced solid tumours: The Gustave Roussy experience. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Ribrag V. Toward common response evaluation criteria for solid tumors and lymphomas: RECIL and RECIST? Ann Oncol 2017; 28:1409-1411. [PMID: 28472399 DOI: 10.1093/annonc/mdx209] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2017] [Indexed: 11/13/2022] Open
|
44
|
Le Gouill S, Wermke M, Morschhauser F, Lim S, Salles G, Kloos I, de Burgat V, Becquart M, Paux G, Kraus-Berthier L, Pennaforte S, Stilgenbauer S, Walewski J, Ribrag V. A NEW BCL-2 INHIBITOR (S55746/BCL201) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE FIRST-IN-HUMAN STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_30] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
45
|
Blakemore S, Daigle S, McDonald A, Morschhauser F, Ribrag V, Salles G, McKay P, Tilly H, Schmitt A, Le Gouill S, Fruchart C, Radford J, Zinzani P, Assouline S, Cartron G, Dickinson M, Morin R, Wu H, Sausen M, Clawson A, Ho P, Miao H. PRELIMINARY EVIDENCE OF A MOLECULAR PREDICTOR OF TAZEMETOSTAT RESPONSE, BEYOND EZH2 MUTATION, IN NHL PATIENTS VIA CHARACTERIZATION OF ARCHIVE TUMOR AND CIRCULATING TUMOR DNA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_14] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
46
|
Morschhauser F, Salles G, McKay P, Tilly H, Schmitt A, Gerecitano J, Johnson P, Le Gouill S, Dickinson M, Fruchart C, Lamy T, Chaidos A, Jurczak W, Opat S, Radford J, Zinzani P, Assouline S, Cartron G, Clawson A, Picazio N, Ribich S, Blakemore S, Larus J, Miao H, Ho P, Ribrag V. INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_3] [Citation(s) in RCA: 50] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
47
|
Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker L, Salles G, Tilly H, Lamy T, Gressin R, Hermine O. Rituximab maintenance after autologous stem-cell transplantation in patients with mantle cell lymphoma, final result of the LyMA trial conducted on behalf the LYSA group. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_74] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
48
|
Zinzani P, Fanale M, Chen R, Armand P, Johnson N, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos T, Tomita A, von Tresckow B, Shipp M, Zhang Y, Balakumaran A, Moskowitz C. PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE-087 STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_125] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
49
|
Stamatoullas A, Ghesquières H, Quittet P, Morschhauser F, Ribrag V, Brice P. PHASE I/II STUDY OF BRENTUXIMAB VEDOTIN IN REFRACTORY/RELAPSED HODGKIN LYMPHOMA PATIENTS TREATED BY CHEMOTHERAPY (ICE) IN SECOND LINE BEFORE AUTOLOGOUS TRANSPLANTATION. Hematol Oncol 2017. [DOI: 10.1002/hon.2440_6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
50
|
Ribrag V, Feugier P, Doorduijn J, Delfau-Larue M, Hermine O, Kluin-Nelemans H, Dasilva M, Lopez-Hernandez A, Walewski J, Szymczyk M, Pott C, Homburg C, Van der Velden V, Gameiro P, Garcia-Sanz R, Ladetto M, van Krieken H, Cabeçadas J, Rymkiewicz G, Klapper W, Hoster E, Le Gouill S, Dreyling M. MCL-R2 ELDERLY: A PHASE III STUDY OF THE EUROPEAN MCL NETWORK
ASSESSING EFFICACY OF ALTERNATING IMMUNOCHEMOTHERAPY (R-CHOP / R-HAD) AND a RITUXIMAB-LENALIDOMIDE MAINTENANCE. Hematol Oncol 2017. [DOI: 10.1002/hon.2440_3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|